These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37615010)

  • 1. Health Economics in the Field of Prosthetics and Orthotics: A Global Perspective.
    Kannenberg A; Seidinger S
    Can Prosthet Orthot J; 2021; 4(2):35298. PubMed ID: 37615010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editor's Perspective on Health Economics in Prosthetics and Orthotics.
    Raschke SU
    Can Prosthet Orthot J; 2021; 4(2):37135. PubMed ID: 37615006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report.
    Perugini M; Johnson TJ; Beume TM; Dong OM; Guerino J; Hu H; Kerr K; Kindilien S; Nuijten M; Ofili TU; Taylor M; Wong A; Freijer K
    Value Health; 2022 May; 25(5):677-684. PubMed ID: 35500942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of New Drug Accessibility and Price Between Japan and Major European Countries.
    Takayama A; Narukawa M
    Ther Innov Regul Sci; 2017 Sep; 51(5):604-611. PubMed ID: 30231682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
    Enzing JJ; Knies S; Engel J; IJzerman MJ; Sander B; Vreman R; Boer B; Brouwer WBF
    Cost Eff Resour Alloc; 2022 Aug; 20(1):46. PubMed ID: 36045377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Health Economics and Outcomes Research in Prosthetics and Orthotics.
    Miller TA; Wurdeman S; Paul R; Forthofer M
    Can Prosthet Orthot J; 2021; 4(2):35959. PubMed ID: 37615002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic evaluation in orthotics and prosthetics: a systematic review protocol.
    Clarke L; Dillon M; Shiell A
    Syst Rev; 2019 Jun; 8(1):152. PubMed ID: 31248460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual health services.
    Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
    GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Market access and value-based pricing of digital health applications in Germany.
    Gensorowsky D; Witte J; Batram M; Greiner W
    Cost Eff Resour Alloc; 2022 Jun; 20(1):25. PubMed ID: 35698135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemplating Health Economics, Coding and Reimbursement in Orthotics, Prosthetics and Pedorthics.
    Highsmith MJ; Fantini CM; Smith DG
    Can Prosthet Orthot J; 2021; 4(2):36125. PubMed ID: 37614990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 14. European Pharmaceutical Pricing and Reimbursement--SMi's 21st Annual Meeting (October 5-6, 2015--London, UK).
    Kibble A; D'Souza P
    Drugs Today (Barc); 2015 Oct; 51(10):609-12. PubMed ID: 26583303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
    Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
    Gandjour A
    Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.